Noracetildenafil

Catalog No. :
ACMCFJ407
CAS No. :
949091-38-7
Molecular Formula :
C24H32N6O3
Molecular Weight :
452.56

IUPAC Name:5-(2-ethoxy-5-(2-(4-methylpiperazin-1-yl)acetyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

Noracetildenafil structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NameNoracetildenafil
IUPAC Name5-(2-ethoxy-5-(2-(4-methylpiperazin-1-yl)acetyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one
Molecular FormulaC24H32N6O3
Molecular Weight452.56
SMILESO=C1C(N(C)N=C2CCC)=C2N=C(C3=CC(C(CN4CCN(C)CC4)=O)=CC=C3OCC)N1
InChI KeyBEAXWKCHSPVXQB-UHFFFAOYSA-N
SynonymNor-acetildenafil;5-[2-Ethoxy-5-[2-(4-Methyl-1-piperazinyl)acetyl]phenyl]-1,6-dihydro-1-Methyl-3-propyl-;5-[2-Ethoxy-5-[2-(4-methyl-1-piperazinyl)acetyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-7H-pyrazolo[4,3-d]pyrimidin-7-one;Nor-acetildenafill 949091-38-7;5-[2-ethoxy-5-[2-(4-methylpiperazin-1-yl)acetyl]phenyl]-1-methyl-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-7-one;7H-Pyrazolo[4,3-d]pyrimidin-7-one, 5-[2-ethoxy-5-[2-(4-methyl-1-piperazinyl)acetyl]phenyl]-1,6-dihydro-1-methyl-3-propyl-;Nor-acetildenafil Solution in Methanol, 100μg/mL;Demethyl Acetildenafil
CAS No.949091-38-7

Synthetic Route by SureRoute

1. ACMCFJ407 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACJACD865 route compound structure diagram
    ACJACD86534352-59-5 In Stock
  4. Then
  5. ACMCFJ407 route product structure diagram
    ACMCFJ407949091-38-7
Inquiry

2. ACMCFJ407 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACMCFJ407 route product structure diagram
    ACMCFJ407949091-38-7
Inquiry

Comments (0)